AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects

Phase 1 Completed 12 enrolled Pfizer

RandomizedCrossoverOpen-labelBasic science

Summary

Phase 1, open label, single dose, 3 way crossover study to evaluate the bioavailability of a solid dose formulation of PF 04965842 relative to a suspension formulation under fasting conditions and the effect of food on the bioavailability of the solid dosage formulation of PF 04965842 in healthy subjects.

Timeline

Start: 2014-06
Primary completion: 2014-08
Completion: 2014-08

Publications

Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis. Clin Pharmacokinet. 2022 May;61(5):709-723. doi: 10.1007/s40262-021-01104-z. Epub 2022 Jan 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abrocitinib	Small molecule	400 mg	Oral

Indications

No indication recorded.